US stock · Healthcare sector · Biotechnology
Company Logo

Geron Corporation

GERNNASDAQ

1.29

USD
- -
(- -)
Market Closed
-179.22P/E
-3Forward P/E
-6.91P/E to S&P500
486.907MMarket CAP
- -Div Yield

Geron Corporation

NASDAQ:GERN

RECENT
PRICE

1.29

P/E
RATIO

-179.22

(PEG:-1.79)

P/E RATIO
RELATIVE
TO S&P

-6.91

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.98 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

0.05

(0.47)

(0.41)

- -

0.10

(0.49)

(0.40)

- -

0.04

(0.79)

(0.57)

- -

0.02

(0.80)

(0.51)

- -

0.04

(1.14)

(0.46)

0.00

0.02

(0.78)

(0.51)

- -

0.02

(0.54)

(0.44)

- -

0.01

(0.30)

(0.29)

- -

0.01

(0.23)

0.06

- -

0.23

0.00

(0.15)

- -

0.04

(0.19)

(0.12)

- -

0.01

(0.18)

(0.13)

- -

0.01

(0.15)

(0.12)

- -

0.00

(0.36)

(0.23)

- -

0.00

(0.28)

(0.25)

- -

0.00

(0.00)

- -

- -

0.00

(0.01)

(0.23)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.01

2.63

0.04

2.77

0.03

2.15

0.02

1.96

0.01

1.97

0.00

1.18

0.01

0.67

0.00

0.47

0.00

0.85

0.00

0.90

0.00

0.77

- -

0.65

0.00

1.01

0.00

0.71

0.00

0.78

- -

0.39

0.00

0.42

CAPEX per share

Book Value per share

66

74

78

88

98

125

127

128

154

158

159

159

177

190

271

328

330

Comm.Shares outs.(m)

(15.0)

(0.8)

- -

(14.3)

(0.8)

- -

(5.1)

(0.2)

- -

(7.5)

(0.1)

- -

(4.6)

(0.2)

0.0%

(4.5)

(0.3)

- -

(3.0)

(0.2)

- -

(7.5)

(0.4)

- -

(12.4)

(0.7)

- -

12,952.1

647.0

- -

(14.4)

(0.7)

- -

(13.3)

(0.6)

- -

(20.8)

(0.8)

- -

(4.0)

(0.2)

- -

(5.8)

(0.2)

- -

(4,373.6)

(145.7)

- -

(179.2)

(6.9)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$101 m.

Total assets
$198 m.

Long-term debt
$54 m.

Cash and equiv.
$31 m.

Goodwill - -

Retained earnings $(1,302) m.

Common stock 332 m. shares

Market Capitalisation
$487 m. (as of 27/5/22)

2

(3,942.4)%

3

(2,648.9)%

1

(3,036.5)%

1

(3,149.3)%

36

(1.5)%

6

(497.3)%

1

(2,746.9)%

1

(2,914.9)%

0

(15,762.0)%

0

(30,400.4)%

0

(384,287.9)%

0

(16,071.0)%

Revenue (m)

Operating margin

2

(97)

1

(69)

0

(38)

0

(36)

0

0

0

(30)

0

(28)

0

(27)

1

(69)

1

(76)

- -

(0)

1

(2)

Depreciation (m)

Net profit (m)

- -

(3,972.6)%

- -

(2,542.7)%

- -

(2,991.3)%

- -

(3,093.7)%

- -

0.1%

- -

(479.3)%

- -

(2,621.2)%

- -

(2,534.4)%

- -

(14,901.7)%

- -

(29,888.1)%

- -

(391.4)%

- -

(25,643.6)%

Income tax rate

Net profit margin

112

- -

147

84

- -

86

59

- -

60

112

- -

131

109

- -

142

108

- -

122

89

- -

104

159

- -

178

113

- -

135

169

24

211

142

4

126

129

54

97

Working capital (m)

Long-term debt (m)

Equity (m)

- -

(60.4)%

(66.1)%

(80.1)%

(68.8)%

(80.4)%

(64.1)%

(56.9)%

(64.2)%

(27.2)%

(20.6)%

(27.3)%

0.1%

0.1%

0.0%

(24.1)%

(22.6)%

(24.1)%

(26.8)%

(25.2)%

(26.9)%

(15.2)%

(14.6)%

(15.2)%

(49.9)%

(41.4)%

(50.7)%

(31.2)%

(27.7)%

(35.8)%

(0.1)%

(0.1)%

(0.1)%

(1.1)%

(0.8)%

(2.5)%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

139

136

161

Receivables

1

1

2

Inventory

- -

- -

- -

Other

1

3

151

Current assets

142

200

187

Acc. Payable

1

7

7

Debt due

0

1

51

Other

27

23

(12)

Current liab.

28

31

46

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

10.6%

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

Geron Corporation (US) started trading on July 3, 1996 (cik: 0000886744), operates in the Healthcare sector (Biotechnology industry), has 69 full-time employees, and is led by Dr. John Scarlett. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

-47.51%

292.88%

Cash flow

- -

- -

Earnings

15.24%

-7156.32%

Dividends

- -

- -

Book value

15.82%

14.60%

Insider trading

Type

Shares

Date

Spiegel Robert J.

Award

125,000

05/10/22

Lawlis V Bryan

Award

125,000

05/10/22

Molineaux Susan

Award

125,000

05/10/22

O'Farrell Elizabeth G.

Award

125,000

05/10/22

Bir Dawn Carter

Award

125,000

05/10/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

0

0

0

0

0

2021

0

0

0

(0)

0

2022

0

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

(0.06)

(0.06)

(0.07)

(0.09)

-0.28

2021

(0.08)

(0.09)

(0.08)

0.26

- -

2022

(0.09)

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -

06/18/2021

Adobe, Smith & Wesson, Orphazyme: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...